IOL Chemicals and Pharmaceuticals Limited

IOL Chemicals and Pharmaceuticals Limited

IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th September 2026.

IOL Chemicals and Pharmaceuticals Limited

IOL Chemicals and Pharmaceuticals Limited has been granted a Certificate of Suitability (CEP) by the European Directorate for the Quality of Medicines & HealthCare (EDQM) for its Active Pharmaceutical Ingredient (API) product 'FENOFIBRATE - Process II'. This is in addition to the existing CEP held by the company for 'Fenofibrate'.

IOL Chemicals and Pharmaceuticals Limited

IOL Chemicals and Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. The Trading Window for dealing in the securities of the Company shall remain closed for all Designated Persons and their Immediate Relatives from 1st October 2026 until the expiry of 48 hours after the declaration of the financial results for the quarter and half year ended 30th September 2026.

IOL Chemicals and Pharmaceuticals Limited

IOL Chemicals and Pharmaceuticals Limited has received REACH certification/registration for its product 'Triacetin' under the EU-REACH framework, enabling the company to export the product across European Union countries.

IOL Chemicals and Pharmaceuticals Limited

IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about a scheduled analyst/institutional investor meeting on September 29, 2026, where the management will discuss past financial results and publicly available information.

IOL Chemicals and Pharmaceuticals Limited

IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about the schedule of an Analyst/Institutional Investor Meeting to be held on September 28, 2026, where the management will discuss past financial results and information already available in the public domain.

IOL Chemicals and Pharmaceuticals Limited

IOL Chemicals and Pharmaceuticals Limited has dispatched reminder letters to shareholders to update their Know Your Customer (KYC) details, as per SEBI regulations.

IOL Chemicals and Pharmaceuticals Limited

IOL Chemicals and Pharmaceuticals Limited has announced three strategic growth initiatives, involving a proposed investment of approximately INR500 crores, to expand its Ibuprofen capacity, establish a new CDMO facility, and set up a dedicated specialty chemical facility. The initiatives are expected to contribute an incremental 25-30% to the company's top line over the coming years.

IOL Chemicals and Pharmaceuticals Limited

IOL Chemicals and Pharmaceuticals Limited has made an audio recording of a business update call with investors and analysts available on its website.

IOL Chemicals and Pharmaceuticals Limited

IOL Chemicals and Pharmaceuticals Limited has scheduled a business update call with investors and analysts to discuss recent business developments and strategic growth initiatives.

IOL Chemicals and Pharmaceuticals Limited

IOL Chemicals and Pharmaceuticals Limited has announced expansion of Ibuprofen capacity, new CDMO business for pharmaceutical formulations, and dedicated specialty chemicals manufacturing facility under long-term tolling arrangement.

IOL Chemicals and Pharmaceuticals Limited

IOL Chemicals and Pharmaceuticals Limited has submitted the voting results and scrutinizer's report for its 39th Annual General Meeting, which was held on September 2, 2026, through video conferencing. The meeting saw a total of 2,935,275 shares voted, with 3 resolutions passed.

IOL Chemicals and Pharmaceuticals Limited

IOL Chemicals and Pharmaceuticals Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 02, 2026.

IOL Chemicals and Pharmaceuticals Limited

IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about a scheduled analyst/institutional investor meeting on 3rd September 2026, where the management will discuss past financial results and publicly available information.

IOL Chemicals and Pharmaceuticals Limited

IOL Chemicals and Pharmaceuticals Limited has announced its Q1 FY27 earnings conference call transcript, highlighting a strong start to the financial year with healthy demand across key products, improved capacity utilization, and favorable product mix. The company has made progress in diversifying its API portfolio beyond ibuprofen, with non-ibu products contributing 43% of pharmaceutical revenue in Q1 FY27, up from 36% in Q1 FY26.

IOL Chemicals and Pharmaceuticals Limited

IOL Chemicals and Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication regarding Special Window for Transfer-cum-Dematerialisation of Physical Securities.

IOL Chemicals and Pharmaceuticals Limited

IOL Chemicals and Pharmaceuticals Limited has made available the audio recording of its analysts/investors call regarding its Q1 FY2027 financial results.

IOL Chemicals and Pharmaceuticals Limited

IOL Chemicals and Pharmaceuticals Limited has released its Q1 FY27 standalone performance highlights, showing revenue from operations at ₹756.3 Cr, a 37.1% YoY increase, with EBITDA at ₹111.7 Cr and PAT at ₹64.5 Cr, representing 60.7% and 89.9% YoY growth respectively.

IOL Chemicals and Pharmaceuticals Limited

IOL Chemicals and Pharmaceuticals Limited has submitted the newspaper publication of un-audited Financial Results for the quarter ended 30th June 2026 to the National Stock Exchange of India Ltd.

IOL Chemicals and Pharmaceuticals Limited

IOL Chemicals and Pharmaceuticals Limited has announced its Q1 FY27 results, reporting a record quarterly performance with highest-ever revenue, driven by improved capacity utilisation, favourable product mix and operational efficiencies. The company's Pharmaceuticals business saw a 43% YoY revenue growth and 72% YoY EBIT growth, while the Chemicals business delivered 29% YoY revenue growth and 193% YoY EBIT growth.